NBC News: Johnson & Johnson to deliver 11 million vaccine doses next week, Biden administration says

NBC News: Johnson & Johnson to deliver 11 million vaccine doses next week, Biden administration says. “Johnson & Johnson is set to deliver 11 million doses of its single-shot Covid-19 vaccine to the U.S. next week, the White House announced, after concerns the company could fall short of its production goal of 20 million doses by the end of the month. The U.S. received 4 million doses of the Johnson & Johnson vaccine shortly after it was cleared for use at the end of February. But since then there has been a lag in production as the manufacturer scaled up operations.”

Route Fifty: Cities Direct Johnson & Johnson Vaccine to Homeless Populations

Route Fifty: Cities Direct Johnson & Johnson Vaccine to Homeless Populations. “City health departments across the country are planning to use the newly approved Johnson & Johnson coronavirus vaccine to target homeless and other hard-to-reach populations—touting the easy logistics with the single-dose shot. But to avoid sewing confusion and distrust among the public, health experts caution that officials need to be transparent about the reasons why certain groups are getting a specific brand of the vaccine.”

‘They just were not all in’: How the White House convinced two pharmaceutical giants to collaborate on a vaccine (CNN)

CNN: ‘They just were not all in’: How the White House convinced two pharmaceutical giants to collaborate on a vaccine. “President Joe Biden’s coronavirus response team learned two things his first week in office: Johnson & Johnson’s one-shot coronavirus vaccine was highly effective — but the company was millions of doses behind its production schedule.”

Mashable: Why all 3 U.S. vaccines are excellent options

Mashable: Why all 3 U.S. vaccines are excellent options. “All the FDA-authorized vaccines (there are currently three) are outstanding options, according to infectious disease experts. Why? ‘All of them look great at preventing disease that results in hospitalization and death,’ emphasized Dr. Thomas Russo, the chief of infectious disease at the University of Buffalo’s Jacobs School of Medicine and Biomedical Sciences. Here’s what to know.”

New York Times: One and Done: Why People Are Eager for Johnson & Johnson’s Vaccine

New York Times: One and Done: Why People Are Eager for Johnson & Johnson’s Vaccine. “Since Johnson & Johnson revealed data showing that its vaccine, while highly protective, had a slightly lower efficacy rate than the first shots produced by Moderna and Pfizer-BioNTech, health officials have feared the new shot might be viewed by some Americans as the inferior choice. But the early days of its rollout suggest something different: Some people are eager to get it because they want the convenience of a single shot.”

Biden to announce ‘historic partnership’: Merck will help make Johnson & Johnson coronavirus vaccine, officials say (Washington Post)

Washington Post: Biden to announce ‘historic partnership’: Merck will help make Johnson & Johnson coronavirus vaccine, officials say. “President Biden will announce Tuesday that pharmaceutical giant Merck & Co. will help make Johnson & Johnson’s single-shot coronavirus vaccine — an unusual pact between fierce competitors that could sharply boost the supply of the newly authorized vaccine, according to senior administration officials.”

CNET: FDA panel gives Johnson & Johnson’s one-shot COVID-19 vaccine green light

CNET: FDA panel gives Johnson & Johnson’s one-shot COVID-19 vaccine green light. “An advisory panel for the US Food and Drug Administration has recommended Johnson & Johnson’s single-dose COVID-19 vaccine be given the green light by the FDA. The FDA Vaccines and Related Biological Products Advisory Committee unanimously voted Friday afternoon to approve the vaccine. The next step will be emergency approval from the FDA itself.”

Houston Chronicle: J&J vaccine protects monkeys from Covid with single shot

Houston Chronicle: J&J vaccine protects monkeys from Covid with single shot. “Johnson & Johnson’s experimental coronavirus vaccine protected a group of macaques with a single shot in an early study, prompting the U.S. drugmaker to start trials in humans this month. All of the animals that were exposed to the pandemic-causing pathogen six weeks after the injection were immune except one, who showed low levels of the virus, according to a study published in the medical journal Nature. The health-care behemoth kick-started human trials on July 22 in Belgium and in the U.S. earlier this week.”

CNBC: Johnson & Johnson hopes to begin late-stage coronavirus vaccine trial ahead of schedule in September

CNBC: Johnson & Johnson hopes to begin late-stage coronavirus vaccine trial ahead of schedule in September. “The company is in talks with the National Institutes of Health to move up the timeline for the trial, J&J’s Chief Scientific Officer Dr. Paul Stoffels said during an earnings call with investors Thursday. The company announced earlier in the day that it plans to enter a phase one human trial next week, which will include more than 1,000 participants.”

FiercePharma: J&J tracks the path to a COVID-19 vaccine in new online news series

FiercePharma: J&J tracks the path to a COVID-19 vaccine in new online news series. “What will it take to develop a vaccine for COVID-19? Johnson & Johnson is taking viewers behind the scenes with an original online video series. Beginning Tuesday, producer and journalist Lisa Ling will host a program titled, ‘The Road to a Vaccine.’ Each 30-minute show will air live online on Tuesdays on Facebook, Twitter, LinkedIn and JNJ.com.”